Zidovudine
- Generic Name
- Zidovudine
- Brand Names
- Combivir, Retrovir, Trizivir
- Drug Type
- Small Molecule
- Chemical Formula
- C10H13N5O4
- CAS Number
- 30516-87-1
- Unique Ingredient Identifier
- 4B9XT59T7S
- Background
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem]
- Indication
Used in combination with other antiretroviral agents for the treatment of human immunovirus (HIV) infections.
- Associated Conditions
- HIV Transmission, Human Immunodeficiency Virus (HIV) Infections, Perinatal HIV transmission
- Associated Therapies
- -
A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 60
- Registration Number
- NCT00002183
- Locations
- 🇺🇸
UCSD, San Diego, California, United States
🇺🇸Univ of Colorado Health Sciences Ctr, Denver, Colorado, United States
🇺🇸AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine or Dideoxyinosine in HIV Positive, Asymptomatic and Symptomatic Individuals
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Chiron Corporation
- Registration Number
- NCT00001997
- Locations
- 🇺🇸
Dr David R Senechek, San Francisco, California, United States
Retrovir Capsules in the Treatment of HIV-Infected Patients in Renal Failure
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Registration Number
- NCT00002047
- Locations
- 🇺🇸
Univ of Maryland at Baltimore, Baltimore, Maryland, United States
The Safety and Effectiveness of Retrovir Plus HIVID Combined With Either Nevirapine or Invirase in the Treatment of HIV Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Parexel
- Target Recruit Count
- 225
- Registration Number
- NCT00002347
- Locations
- 🇺🇸
PAREXEL Intl Corp / InterCo Collaboration Ctr, Waltham, Massachusetts, United States
A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 825
- Registration Number
- NCT00002378
- Locations
- 🇺🇸
Northwestern Univ Med Ctr, Chicago, Illinois, United States
🇺🇸Lehigh Valley Hosp, Allentown, Pennsylvania, United States
🇺🇸North Texas Infectious Disease Consultants, Dallas, Texas, United States
A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-06-07
- Target Recruit Count
- 900
- Registration Number
- NCT00000919
- Locations
- 🇺🇸
Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States
🇺🇸Marin County Specialty Clinic, San Rafael, California, United States
🇺🇸Emory Hemo Comp Evaluation Clinic / East TN Comp Hemo Ctr, Atlanta, Georgia, United States
A Comparison of Lamivudine and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Not Used Zidovudine in the Past
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-12-12
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 320
- Registration Number
- NCT00002320
- Locations
- 🇺🇸
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
🇺🇸Chicago Ctr for Clinical Research, Chicago, Illinois, United States
🇺🇸Nicholaos Bellos, Dallas, Texas, United States
The Effects of AZT and Ibuprofen on HIV-Infected Patients With Hemophilia
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- University of Pittsburgh
- Registration Number
- NCT00002276
- Locations
- 🇺🇸
Hemophilia Ctr of Western PA / Univ of Pittsburgh, Pittsburgh, Pennsylvania, United States
The Safety and Effectiveness of Lamivudine Plus Zidovudine, Used With and Without 1592U89, in HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 210
- Registration Number
- NCT00002389
- Locations
- 🇺🇸
East Bay AIDS Ctr, Berkeley, California, United States
🇺🇸Kraus Med Partners, Los Angeles, California, United States
🇺🇸Univ of Miami Dept of Medicine, Miami, Florida, United States
Trial of an Alternative Dosing Regimen of Oral Retrovir in Patients With AIDS or Advanced ARC
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Registration Number
- NCT00002020
- Locations
- 🇺🇸
Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States
🇺🇸Northwestern Univ Med School, Chicago, Illinois, United States
🇺🇸North Jersey Community Research Initiative, Newark, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.